Syros Pharmaceuticals, Inc.
SYRS
$0.032
-$0.0067-17.31%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 84.07% | 35.66% | 84.41% | -1,248.64% | -32.69% |
| Total Depreciation and Amortization | -46.90% | -49.08% | -47.65% | -50.07% | 15.91% |
| Total Amortization of Deferred Charges | 2.80% | -17.12% | 12.59% | 11.11% | -97.25% |
| Total Other Non-Cash Items | -300.41% | -154.30% | -274.38% | 240.80% | 240.11% |
| Change in Net Operating Assets | 318.60% | -150.35% | 60.24% | 953.37% | 61.12% |
| Cash from Operations | 35.06% | -32.52% | 15.73% | 40.28% | 10.98% |
| Capital Expenditure | -- | -- | -- | 94.36% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -24.15% | 3.31% | -100.00% | 339.26% |
| Cash from Investing | -100.00% | -23.86% | 4.30% | -95.97% | 362.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 96.00% | 98.66% |
| Issuance of Common Stock | -- | -20.14% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00% | -70.71% | -400.00% | 505.31% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -541.92% | -142.70% | 10.68% | 747.97% | -102.87% |